David Allen Blubaugh
davidblubaugh2000@yahoo.com

1-937-304-7952

October 9, 2023

Dear Dr. John Campbell,

I hope this letter finds you in good health and high spirits. I am writing to you with a sense of urgency and a strong desire to contribute to the advancement of medical knowledge and the betterment of public health. My name is David Allen Blubaugh, and **I HAVE NOT** received **ANY** of the current or past COVID-19 mRNA vaccines. I am deeply convinced that my unique position presents an opportunity to gain valuable insights into the potential effects of these vaccines on DNA and RNA, specifically in the context of your thoughtful considerations and YouTube discussions related to DNA mutations, RNA alterations, inflammatory responses, mitochondrial dysfunction, genotoxic effects, epigenetic changes, immune system dysregulation, cellular proliferation, hormonal changes, metabolic disturbances, preexisting conditions, and unforeseen drug interactions. These unforeseen drug interactions would be regarding those vaccinated population sets that have received multiple COVID-19 mRNA vaccinations and bivalent booster vaccinations from the many different vaccine manufacturers (Pfizer, Moderna, and Johnson & Johnson, etc).

First and foremost, I would like to express my profound appreciation for your dedication to disseminating vital information related to healthcare and the COVID-19 pandemic on your YouTube Channel. Your commitment to educating the public during these challenging times has been an invaluable resource for countless individuals, including myself. It is through your diligent work that I have become more aware of the complexities surrounding mRNA vaccines and their potential lethal implications regarding aggressive forms of Cancer and Myocarditis.

Considering the extensive discussions surrounding mRNA vaccines, I firmly believe that a comprehensive examination of the effects of these vaccines on individuals who have not received them is essential. By comparing individuals who have received medical treatment (mRNA vaccines, in this case) to those who have not, we can potentially uncover crucial insights into the various factors you have outlined in your many YouTube considerations.

Specifically, I am interested in understanding how the introduction of mRNA vaccines may impact DNA and RNA within the human body and whether any alterations or mutations occur that could lead to conditions such as aggressive forms of cancer and myocarditis. It is important to emphasize that my intention is to question the safety and efficacy of these vaccines and to contribute to the scientific understanding of their potential effects and consequences.

As an infinitely concerned and engaged member of society, I am fully prepared to cooperate with medical professionals, researchers, and experts to undergo the necessary tests and

evaluations. I am committed to ensuring that this study adheres to the highest ethical and scientific standards and contributes positively to public health.

I understand that such research endeavors require careful planning, coordination, and resources. However, I am willing to dedicate my time, effort, and resources to this endeavor because I believe that the knowledge gained from such a study could have far-reaching implications for our understanding of COVID-19 mRNA vaccines and their broader applications in medicine.

In closing, Dr. Campbell, I respectfully request your guidance, support, and expertise in pursuing this research endeavor. Your extensive knowledge and experience in the field of medicine and your commitment to evidence-based healthcare make you an ideal partner in this pursuit.

Thank you for considering my proposal, and I eagerly await your response. Together, we can contribute to the advancement of science, the betterment of public health, and the assurance of a safer and healthier future for all.

Sincerely,

David Allen Blubaugh

Please feel free to make any adjustments or additions to the letter and attached discussion as needed to convey your message effectively.

The following discussions would be my hopeful eventual project creation of developing a "grassroots" organization to conduct, compare, and contrast the number of tests required to compare my and other (non mRNA vaccinated population) DNA/RNA status and other biological signals and conditions with those individuals that have received ANY of the mRNA COVID-19 vaccines since their introduction in 2019-2023 timeframe.

When comparing a person who did not receive medical treatment (NO mRNA COVID-19 vaccines) to someone who did receive medical treatment (various mRNA COVID-19 vaccines), especially in the context of the considerations you provided related to DNA mutations, RNA alterations, inflammatory responses, mitochondrial dysfunction, genotoxic effects, epigenetic changes, immune system dysregulation, cellular proliferation, hormonal changes, metabolic disturbances, preexisting conditions, and unforeseen drug interactions, there can be both similarities and differences depending on the specific treatment and individual characteristics. Here's how they might be similar or different:

DNA Mutations:

a. Induction of DNA mutations by treatment-induced chemicals or radiation exposure: Those who received treatment (various mRNA COVID-19 vaccines) may be at risk of treatment-induced DNA mutations, while those who didn't receive treatment would not have this specific risk.

b. Activation of latent oncogenes due to treatment-related cellular stress: Those who received treatment (various mRNA COVID-19 vaccines) might experience this risk, which would not apply to those who did not receive treatment.

c. Inhibition of DNA repair mechanisms leading to the accumulation of mutations: Those who received treatment may be at risk of inhibited DNA repair mechanisms, while those without treatment wouldn't face this risk.

RNA Alterations:

a. Dysregulation of RNA processing machinery, causing the production of abnormal RNA molecules: This risk may apply more to those who received treatment, especially if the treatment impacts RNA processing.

b. Interference with microRNA function, resulting in aberrant gene expression patterns: Again, this risk would likely be more relevant to those who received treatment.

Inflammatory Responses:

a. Treatment-induced inflammation triggering chronic tissue damage and genomic instability: This risk would generally be associated with those who received treatment, as the absence of treatment typically wouldn't induce inflammation.

b. Overactivation of the immune system leading to autoimmune reactions against healthy tissues: This risk could occur in individuals who received treatment but not in those who did not.

Mitochondrial Dysfunction:

a. Disruption of mitochondrial function by medications, causing oxidative stress and DNA damage: Those who received treatment may face this risk, while those who didn't receive treatment wouldn't be exposed to medication-induced mitochondrial disruption.

b. Impaired mitochondrial repair mechanisms due to treatment, resulting in mitochondrial mutations: Again, this risk would be associated with individuals who received treatment.

Genotoxic Effects:

a. Direct genotoxicity of the treatment substance, leading to DNA damage: Those who received treatment would be at risk of direct genotoxicity, which would not apply to those who did not receive treatment.

b. Induction of DNA double-strand breaks by treatment-related factors: This risk would be specific to individuals who received treatment.

Epigenetic Changes:

a. Alterations in DNA methylation patterns that could promote cancerous or inflammatory gene expression: Those who received treatment may experience this risk, whereas those without treatment wouldn't.

b. Modulation of histone modifications influencing gene regulation and cellular behavior: This risk would generally be relevant to individuals who received treatment.

Immune System Dysregulation:

a. Treatment-induced suppression of the immune system, allowing cancerous or inflammatory cells to evade detection: This risk would apply primarily to those who received treatment.

b. Activation of immune cells that attack healthy tissues (autoimmunity): Autoimmune reactions could occur in individuals who received treatment but would not be expected in those who did not receive treatment.

Cellular Proliferation:

a. Stimulation of cell growth by the treatment, potentially leading to uncontrolled cell division: This risk would primarily pertain to individuals who received treatment.

b. Inhibition of cell cycle checkpoints, allowing the unchecked growth of cancerous cells: This risk would apply to those who received treatment, not to those without treatment.

Hormonal Changes:

a. Disruption of hormonal balance by the treatment, influencing cancer-promoting pathways: Those who received treatment may experience hormonal disruptions, which would not apply to those without treatment.

b. Treatment-induced hormonal imbalances leading to myocarditis-related issues: This risk would be associated with individuals who received treatment.

Metabolic Disturbances:

a. Changes in cellular metabolism due to treatment, promoting cancer or cardiac abnormalities: Those who received treatment may experience metabolic changes, while those without treatment would not.

b. Altered metabolism leading to increased oxidative stress and DNA damage: This risk would be more relevant to individuals who received treatment.

Preexisting Conditions:

a. Interactions between the treatment and preexisting genetic predispositions to cancer or myocarditis: Those with preexisting genetic predispositions may be at risk of interactions if they received treatment, while those who did not receive treatment would not face this specific risk.

b. Treatment exacerbating underlying conditions that increase cancer or myocarditis risk: This risk would be relevant to individuals with underlying conditions who received treatment.

Unforeseen Drug Interactions:

a. unexpected interactions between the medical treatment and other medications or substances leading to harmful effects: Those who received treatment may be at risk of these interactions, whereas those without treatment would not be exposed to these potential risks.

b. Combined effects of multiple treatments increase the risk of DNA or RNA alterations: This risk would be associated with individuals who received multiple treatments, not those without treatment. These multiple treatments would include vaccinated population sets that have received multiple COVID-19 vaccinations and bivalent booster vaccinations from the forementioned vaccine manufacturers.

In summary, individuals who receive medical treatment, depending on the specific treatment and their characteristics, may be at risk of various genetic, epigenetic, immunological, and metabolic changes that could lead to adverse health outcomes such as aggressive forms of cancer and myocarditis. Those who did not receive any treatment would generally not be exposed to these specific risks. There should be a statistical significance between the two sets of populations.

The next following discussion would be regarding the type of testing and experimental procedures that should be considered in utilizing, comparing, and contrasting the DNA/RNA status and biological signals and conditions of nonvaccinated individuals, such as myself, with those who did indeed receive COVID-19 mRNA vaccinations:

1. DNA and RNA Sequencing:

Objective: To detect any changes or mutations in DNA and RNA.

Method: Whole-genome sequencing and transcriptome sequencing can be performed on individuals who have received mRNA vaccines and those who have not. This can help identify any differences in genetic material and RNA expression patterns.

2. Genotoxicity Assessment:

Objective: To evaluate if the vaccines induce genotoxic effects.

Method: In vitro tests, such as the Comet assay or micronucleus assay, can assess DNA damage in cell cultures exposed to vaccine components. Animal studies can also evaluate genotoxicity.

3. Inflammatory Responses:

Objective: To measure inflammatory responses and cytokine levels.

Method: Blood samples can be collected from individuals with and without vaccination to measure cytokines, chemokines, and markers of inflammation. This can help assess whether there are treatment-induced inflammatory responses.

4. Mitochondrial Function:

Objective: To assess potential mitochondrial dysfunction.

Method: Mitochondrial function can be evaluated through assays measuring mitochondrial membrane potential, ATP production, and reactive oxygen species (ROS) levels in cells exposed to vaccine components.

5. Epigenetic Changes:

Objective: To investigate alterations in DNA methylation and histone modifications.

Method: Epigenome-wide association studies (EWAS) can be conducted on samples from vaccinated and unvaccinated individuals to identify changes in epigenetic marks.

6. Immune System Dysregulation:

Objective: To examine the effects of vaccines on immune cell populations.

Method: Flow cytometry and immune profiling can be used to assess changes in immune cell subsets, including T cells, B cells, and innate immune cells, following vaccination.

7. Cellular Proliferation:

Objective: To determine if vaccines impact cell proliferation.

Method: Cell proliferation assays can measure the rate of cell division in various cell types exposed to vaccine components.

8. Hormonal Changes:

Objective: To investigate hormonal disruptions.

Method: Hormone levels (e.g., cortisol, sex hormones) can be measured in blood samples collected with and without vaccination to assess any hormonal changes.

9. Metabolic Disturbances:

Objective: To study changes in cellular metabolism.

Method: Metabolomics analyses can identify alterations in metabolic pathways and metabolite concentrations in cells non-exposed or exposed to vaccine components.

10. Preexisting Conditions:

Objective: To assess interactions between vaccines and genetic predispositions.

Method: Genetic screening and association studies can identify individuals with specific genetic variants and evaluate their response to and without vaccination.

11. Unforeseen Drug Interactions:

Objective: To investigate potential interactions with other vaccines or substances.

Method: In vitro studies can assess interactions between vaccine components and common medications. Animal studies can also be conducted to evaluate combined effects.

It's important to emphasize that conducting such research would require collaboration with experts in the fields of genomics, immunology, toxicology, and epidemiology would be essential to design and conduct these studies effectively.

The following FINAL discussion would be regarding the type of testing and experimental procedures that should be considered in utilizing, comparing, and contrasting the biological signals and conditions of bone marrow samples collected from nonvaccinated individuals, such as myself, to those who did receive the various COVID-19 mRNA vaccinations:

Comparing the bone marrow of an individual who did not receive a COVID-19 mRNA vaccination to someone who did receive an mRNA vaccination can provide insights into potential effects on hematopoiesis (the process of blood cell formation) and the bone marrow microenvironment. Several tests and assessments can be performed to make these comparisons and potentially uncover valuable discoveries. Here are some tests that could be conducted and the potential discoveries that could result from such a comparison:

1. Bone Marrow Aspiration and Biopsy:

Objective: To examine the cellular composition and structure of the bone marrow.

Discoveries: Differences in cell populations, cell morphology, and the overall health of the bone marrow can be observed. This can include changes in the numbers and types of blood cells, the presence of abnormal cells, and the presence of fibrosis (excessive scar tissue).

2. Flow Cytometry:

Objective: To analyze the surface markers and characteristics of various bone marrow cells.

Discoveries: Differences in the proportions and characteristics of different cell populations, including hematopoietic stem cells, can be assessed. Changes in the immune cell population can also be identified.

3. Cytogenetic Analysis:

Objective: To examine the chromosomes within bone marrow cells.

Discoveries: Chromosomal abnormalities, such as translocations or deletions, can be identified. These abnormalities may be indicative of treatment-related effects or underlying genetic conditions.

4. Molecular Profiling:

Objective: To assess gene expression patterns and epigenetic changes within the bone marrow.

Discoveries: Changes in gene expression, signaling pathways, and epigenetic modifications that may result from vaccination can be identified. These molecular changes can provide insights into how mRNA vaccines affect bone marrow cells.

5. Hematological Testing:

Objective: To evaluate blood cell counts and markers of hematopoiesis.

Discoveries: Differences in blood cell counts, including red blood cells, white blood cells, and platelets, can be observed. Changes in markers of hematopoiesis may indicate treatment-related effects on blood cell production.

6. Bone Marrow Fibrosis Assessment:

Objective: To assess the presence and severity of fibrosis in bone marrow.

Discoveries: The degree of fibrosis, if present, can be quantified. Treatment-related fibrosis can be identified and may contribute to bone marrow disorders.

7. Metabolic Profiling:

Objective: To analyze the metabolic profile of bone marrow cells.

Discoveries: Changes in metabolic pathways, energy utilization, and metabolite concentrations can be detected. This can provide insights into how mRNA vaccination may influence the metabolic activity of bone marrow cells.

8. Immune Cell Analysis:

Objective: To examine immune cell populations within the bone marrow.

Discoveries: Alterations in immune cell subsets and their activity can be identified. Changes in the immune microenvironment of the bone marrow may be associated with vaccination.

9. Histological Examination:

Objective: To study cell morphology and tissue architecture.

Discoveries: Differences in cell morphology, tissue organization, and the presence of infiltrates or inflammatory responses can be observed.

10. Molecular Genetic Testing:

Objective: To identify mutations or genetic alterations within bone marrow cells.

Discoveries: Specific genetic mutations or alterations that may result from vaccination or interact with the vaccine's effects can be pinpointed.

11. Assessing Therapeutic Response:

Objective: To evaluate the treatment's effectiveness in treating underlying conditions (if applicable) based on changes in the bone marrow.

Discoveries: The impact of vaccination on the progression or management of underlying hematological or bone marrow disorders can be assessed.

12. Detection of Complications:

Objective: To identify any complications related to vaccination.

Discoveries: The presence of complications such as infection, bleeding disorders, or graft-versus-host disease (in the case of stem cell transplantation) can be assessed.

By conducting these tests and assessments, researchers and clinicians can gain insights into the effects of mRNA vaccination on bone marrow composition, function, and overall health. It can also help identify potential treatment-related complications and guide therapeutic decisions.

Dr. John Campbell please let me know if you would like to proceed with collaboration on this endeavor???